FDA reform delayed by summer recess
This article was originally published in Clinica
Executive Summary
FDA reform legislation in both houses of the US Congress has been delayed until after the summer recess and it looks increasingly unlikely that a bill will pass during this session. Nancy Kassebaum failed to secure time for a floor vote on the Senate bill and the House committee postponed its mark-up session scheduled for August 1st.